Senores Pharmaceuticals IPO (Senores Pharmaceuticals Limited IPO)
Senores Pharmaceuticals IPO open for bidding on 20th December 2024 and ends on 24th December 2024.
Senores Pharmaceuticals Limited is a leading player in the pharmaceutical industry, headquartered in Ahmedabad, Gujarat, India. The company specializes in manufacturing and marketing high-quality generic formulations across various therapeutic categories, ensuring accessibility and affordability for patients globally. Established in 2017, Senores has rapidly grown its portfolio to address critical healthcare needs with a robust research and development (R&D) focus.
The company’s product offerings cater to both domestic and international markets, spanning regions such as the United States, Europe, and emerging markets. By adhering to stringent regulatory compliance, Senores has gained approvals from global regulatory authorities like the USFDA and EMA, showcasing its commitment to quality and innovation.
Senores operates through its subsidiaries, including Ratnatris Pharmaceuticals Private Limited and Aavis Pharmaceuticals, enhancing its capabilities in manufacturing and global distribution. The company leverages advanced technologies and state-of-the-art facilities to produce cost-efficient pharmaceuticals.
For more details refer to Senores Pharmaceuticals IPO RHP and Senores Pharmaceuticals IPO Pulse Score
Senores Pharmaceuticals IPO Details
| IPO Date | 20th December 2024 to 24th December 2024 |
| Listing Date | [•] |
| Face Value | ₹10 per share |
| Price Band | ₹372 to ₹391 per share |
| Lot Size | 38 Shares |
| Total Issue Size | [•] shares (aggregating up to ₹582.11 Cr) |
| Fresh Issue | [•] shares (aggregating up to ₹500.00 Cr) |
| Offer for Sale | 21,00,000 shares of ₹10 (aggregating up to ₹82.11 Cr) |
| Issue Type | Book Built Issue IPO |
IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB | >75% |
| NII | <15% |
| bNII | 10% |
| sNII | 5% |
| Retail | <10% |
Senores Pharmaceuticals IPO Timeline
| IPO Open | 20th December 2024 |
| IPO Close | 24th December 2024 |
| Basis Of Allotment | 26th December 2024 |
| Initiation of Refunds | 27th December 2024 |
| Credit of Shares to Demat | 27th December 2024 |
| Listing Date | 30th December 2024 |
Fundamentals
Data as of 30th September 2024
| Market Cap | ₹1,350.70 Cr | P/E Ratio- Pre IPO | 39.77 |
| RoNW* | 8.69% | P/E Ratio- Post IPO | 28.21 |
| RoCE* | 7.59% | P/B Ratio | 5.84 |
| Debt to Equity | 0.76 | PAT Margin | 13.23% |
Note: P/E Ratio -Pre IPO is calculated based on Pre-issue Shareholding and FY Earnings of March 2024. P/E Ratio- Post IPO is calculated based on post-issue shareholding and annualized FY earnings for September 2024. RoCE and RoNW are for six-month period ended September 30, 2024
Senores Pharmaceuticals IPO Objectives
The company proposes to utilize the Net Proceeds towards the funding of the following objects:
- Investment in one of the Subsidiaries, Havix Group, Inc. d/b/a Aavis Pharmaceuticals (“Havix”), to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in the Atlanta Facility;
- Re-payment/pre-payment, in full or in part, of certain borrowings availed by the Company;
- Investment in the Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiary;
- Funding the working capital requirements of the Company;
- Investment in the Subsidiaries, namely, Senores Pharmaceuticals Inc. (“SPI”) and Ratnatris Pharmaceutical Private Limited (“Ratnatris”) to fund their working capital requirements; and
- Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.
Leave a Reply